1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )
                )
            [credentials] => Array
                (
                    [method] => guest
                )
        )
)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )
                )
            [credentials] => Array
                (
                    [method] => guest
                )
        )
)
Table 1: Demographic data of patients presenting with subarachnoid or isolated intraventricular hemorrhage without a causative lesion on CTA
Total Men Women No. of Patients 230 118 112 Mean age (yr) 54 55 54 Age range 19–92 21–92 19–87 SAH found by CT 216 106 110 SAH found by lumbar puncture 14 7 7 Mean time between CTA and DSA (days) 1.5 1.0 2.0 Time range between CTA and DSA (days) 0–110 0–5 0–110 Second follow-up study performed (No. of patients) 169 86 83 Mean time between initial and follow-up study (days) 33 24 42 Time range between initial and follow-up study (days) 0–1836 0–203 0–1836 Second follow-up modality     CTA 54 28 26     DSA 98 45 53     MRI/MRA 17 10 7